trending Market Intelligence /marketintelligence/en/news-insights/trending/TYVdhTQccWP-C-3eMuD2Cg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Agios gets US FDA breakthrough status for cancer treatment Tibsovo

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Agios gets US FDA breakthrough status for cancer treatment Tibsovo

Agios Pharmaceuticals Inc. said the U.S. Food and Drug Administration granted a breakthrough therapy designation to Tibsovo to treat certain patients with a type of blood cancer.

The Cambridge, Mass.-based biotech said Tibsovo, or ivosidenib, was given the status to treat patients with relapsed or refractory myelodysplastic syndrome that have a mutation called isocitrate dehydrogenase 1, or IDH1.

Myelodysplastic syndrome, or MSD, is a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells. Symptoms for the disease include tiredness, weakness and shortness of breath due to low levels of red blood cells, frequent and severe infections because of a lesser number of white blood cells, as well as severe nosebleeds and easy bruising due to an inadequate number of platelets.

Agios is currently evaluating the drug in a phase 1 trial for safety, effects on the human body as well as biochemical and physiological impacts in different types of blood cancers including MSD.

The FDA grants breakthrough designations to new medicines that treat serious or life-threatening conditions and are potentially better than existing therapies. The designation expedites the development and review of the drug.

In November, Agios decided to scrap its plan to seek the FDA's approval for Tibsovo to treat a certain type of bile duct cancer following a meeting with the regulator.

Tibsovo is approved in the U.S to treat certain patients with a type of blood cancer known as acute myeloid leukemia.